The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes
Open accessAbstract
One mechanism contributing to immunologic unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs.We show that mouse tumor-draining LNs (TDLNs) contained a subset of plasmacytoid DCs (pDCs) that constitutively expressed immunosuppressive levels of the enzyme indoleamine 2,3-dioxygenase (IDO).Despite comprising only 0.5% of LN cells, these pDCs in vitro potently suppressed T cell responses to antigens presented by the pDCs themselves and also, in a dominant fashion, suppressed T cell responses to third-party antigens presented by nonsuppressive APCs.Adoptive transfer of DCs from TDLNs into naive hosts created profound local T cell anergy, specifically toward antigens expressed by the transferred DCs.Anergy was prevented by targeted disruption of the IDO gene in the DCs or by administration of the IDO inhibitor drug 1-methyl-D-tryptophan to recipient mice.Within the population of pDCs, the majority of the functional IDO-mediated suppressor activity segregated with a novel subset of pDCs coexpressing the B-lineage marker CD19.We hypothesize that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses.Nonstandard abbreviations used: indoleamine 2,3-dioxygenase (IDO); 1-methyl-D-tryptophan (1MT); mixed leukocyte reaction (MLR); plasmacytoid DC (pDC); regulatory T cell (Treg); T cell receptor (TCR); tumor-draining LN (TDLN). Conflict of interest:The authors have declared that no conflict of interest exists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preclinical models, heightened activity of the Trp-Kyn-AhR pathway has been linked to impairment of antitumor immunity and tumor growth (16,17).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,162
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I. E., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,640
Self-citationModulation of tryptophan catabolism by regulatory T cells
Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,375
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,204
Commitment to the B-lymphoid lineage depends on the transcription factor Pax5
Nutt, S. L., Heavey, B., Rolink, A. G., & Busslinger, M. (1999) · Nature · doi:10.1038/44076 · Cited by 1,179
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y.-C., Golumbek, P. T., Ahmadzadeh, M., Jaffee, E. M., Pardoll, D. M., & Levitsky, H. I. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,159
Research works printed but not linked: 2
- Cuenca, 2003, Cancer Res., 63, 9007
- Almand, 2000, Clin. Cancer Res., 6, 1755
Cited by
Sorted by citations
Items 201–300 of 877
IDO-expressing regulatory dendritic cells in cancer and chronic infection
Popov, A., & Schultze, J. L. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0262-6 · Cited by 111
Regulation of dendritic cells by female sex steroids: Relevance to immunity and autoimmunity
Hughes, G. C., & Clark, E. A. (2007) · Autoimmunity · doi:10.1080/08916930701464764 · Cited by 107
Virus-stimulated plasmacytoid dendritic cells induce CD4+ cytotoxic regulatory T cells
Kawamura, K., Kadowaki, N., Kitawaki, T., & Uchiyama, T. (2005) · Blood · doi:10.1182/blood-2005-04-1737 · Cited by 106
Koyama, M., Hashimoto, D., Aoyama, K., Matsuoka, K., Karube, K., Niiro, H., Harada, M., Tanimoto, M., Akashi, K., & Teshima, T. (2009) · Blood · doi:10.1182/blood-2008-07-168609 · Cited by 105
Iweala, O. I., & Nagler‐Anderson, C. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00431.x · Cited by 106
Amino-acid sensing and degrading pathways in immune regulation
Grohmann, U., Mondanelli, G., Belladonna, M. L., Orabona, C., Pallotta, M. T., Iacono, A., Puccetti, P., & Volpi, C. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.05.004 · Cited by 105
Chamuleau, M. E. D., van de Loosdrecht, A. A., Hess, C. J., Janssen, J. J. W. M., Zevenbergen, A., Delwel, R., Valk, P. J. M., Löwenberg, B., & Ossenkoppele, G. J. (2008) · Haematologica · doi:10.3324/haematol.13113 · Cited by 106
Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion
DeVito, N. C., Plebanek, M. P., Theivanthiran, B., & Hanks, B. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02876 · Cited by 105
Is the CD200/CD200 Receptor Interaction More Than Just a Myeloid Cell Inhibitory Signal?
Minas, K., & Liversidge, J. (2006) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v26.i3.20 · Cited by 107
Zheng, X., Koropatnick, J. D., Chen, D., Velenosi, T. J., Ling, H., Zhang, X., Jiang, N., Navarro, B., Ichim, T. E., Urquhart, B. L., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27710 · Cited by 105
Plasmacytoid Dendritic Cells Regulate Breach of Self-Tolerance in Autoimmune Arthritis
Jongbloed, S. L., Benson, R. A., Nickdel, M. B., Garside, P., McInnes, I. B., & Brewer, J. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.2.963 · Cited by 102
The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer
Cai, J., Qi, Q., Qian, X., Han, J. G., Zhu, X., Zhang, Q., & Xia, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02879-2 · Cited by 103
Modulation of Cancer-Specific Immune Responses by Amino Acid Degrading Enzymes
Timosenko, E., Hadjinicolaou, A. V., & Cerundolo, V. (2016) · Immunotherapy · doi:10.2217/imt-2016-0118 · Cited by 103
Kristeleit, R. S., Давиденко, І., Shirinkin, V., El-Khouly, F., Bondarenko, I., Goodheart, M. J., Горбунова, В. А., Penning, C. A., Shi, J. G., Liu, X., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.005 · Cited by 102
Zakharia, Y., McWilliams, R. R., Rixe, O., Drabick, J. J., Shaheen, M. F., Grossmann, K. F., Kolhe, R. B., Pacholczyk, R., Sadek, R., Tennant, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002057 · Cited by 100
Self-citationExpression of tolerogenic HLA-G molecules in cancer prevents antitumor responses
Rouas‐Freiss, N., Moreau, P., Menier, C., LeMaoult, J., & Carosella, E. D. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.07.003 · Cited by 104
The modulatory effects of lipopolysaccharide‐stimulated B cells on differential T‐cell polarization
Xu, H. M., Liew, L. N., Kuo, I.-C., Huang, C. H., Goh, D. L. M., & Chua, K. Y. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02832.x · Cited by 100
Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients
Speeckaert, R., Vermaelen, K., van Geel, N., Autier, P., Lambert, J., Haspeslagh, M., Gele, M. V., Thielemans, K., Neyns, B., Roche, N. A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.007 · Cited by 100
Tryptophan degradation in autoimmune diseases
Opitz, C. A., Wick, W., Steinman, L., & Platten, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7140-9 · Cited by 102
Expression of Indoleamine 2,3-Dioxygenase and Correlation With Pathological Malignancy in Gliomas
Mitsuka, K., Kawataki, T., Satoh, E., Asahara, T., Horikoshi, T., & Kinouchi, H. (2013) · Neurosurgery · doi:10.1227/neu.0b013e31828cf945 · Cited by 103
Zheng, X., Koropatnick, J. D., Li, M., Zhang, X., Ling, F., Ren, X., Hao, X., Sun, H., Vladau, C., Franek, J. A., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.5639 · Cited by 98
Immunosuppressive Mechanisms of Regulatory Dendritic Cells in Cancer
Shurin, G. V., Ma, Y., & Shurin, M. R. (2013) · Cancer Microenvironment · doi:10.1007/s12307-013-0133-3 · Cited by 102
Takao, M., Okamoto, A., Nikaido, T., Urashima, M., Takakura, S., Saito, M., Saito, M., Okamoto, S., Takikawa, O., Sasaki, H., et al. (2007) · Oncology Reports · doi:10.3892/or.17.6.1333 · Cited by 97
Aggarwal, S., van de Loosdrecht, A. A., Alhan, C., Ossenkoppele, G. J., Westers, T. M., & Bontkes, H. J. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08683.x · Cited by 99
Harnaha, J., Machen, J., Wright, M. F., Lakomy, R., Styche, A. J., Trucco, M., Makaroun, S., & Giannoukakis, N. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-0340 · Cited by 97
The Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance
Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/430394 · Cited by 98
Li, T., Liu, T., Zhu, W., Xie, S., Zhao, Z., Feng, B., Guo, H., & Yang, R. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/11795549211035540 · Cited by 98
Nutrients: Signal 4 in T cell immunity
Raynor, J. L., & Chi, H. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20221839 · Cited by 99
The role of the kynurenine pathway of tryptophan metabolism in cardiovascular disease
Polyzos, K. A., & Ketelhuth, D. F. J. (2015) · Hämostaseologie · doi:10.5482/hamo-14-10-0052 · Cited by 94
Clinical significance of T cell metabolic reprogramming in cancer
Herbel, C., Patsoukis, N., Bardhan, K., Seth, P., Weaver, J. D., & Boussiotis, V. A. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0110-9 · Cited by 99
Jia, L., Schweikart, K. M., Tomaszewski, J. E., Page, J. G., Noker, P. E., Buhrow, S. A., Reid, J. M., Ames, M. M., & Munn, D. H. (2007) · Food and Chemical Toxicology · doi:10.1016/j.fct.2007.07.017 · Cited by 93
Self-citationBrown, I. E., Blank, C., Kline, J., Kacha, A. K., & Gajewski, T. F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4521 · Cited by 91
Manlapat, A., Kahler, D. J., Chandler, P., Munn, D. H., & Mellor, A. L. (2007) · European Journal of Immunology · doi:10.1002/eji.200636690 · Cited by 92
Self-citationIDO1 is an Integral Mediator of Inflammatory Neovascularization
Mondal, A., Smith, C., DuHadaway, J. B., Sutanto‐Ward, E., Prendergast, G. C., Bravo‐Nuevo, A., & Muller, A. J. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.013 · Cited by 92
Signaling defects in anti‐tumor T cells
Frey, A. B., & Monu, N. R. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00606.x · Cited by 91
Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance
Johnson, T. S., & Munn, D. H. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.689405 · Cited by 91
Self-citationThe immunoregulatory role of IDO-producing human dendritic cells revisited
Terness, P., Chuang, J.-J., & Opelz, G. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.12.006 · Cited by 89
Pang, L., Ng, T., Liu, J., Yeung, W.-H. O., Zhu, J., Chiu, T.-L. S., Liu, H., Chen, Z., Lo, C., & Man, K. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.022 · Cited by 87
Ninomiya, S., Hara, T., Tsurumi, H., Hoshi, M., Kanemura, N., Goto, N., Kasahara, S., Shimizu, M., Ito, H., Saito, K., et al. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1093-z · Cited by 87
A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA
Yen, M., Lin, C., Chen, Y., Huang, S.-S., Yang, H., Chang, C., Lei, H.-Y., & Lai, M.-D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1988 · Cited by 88
Zaher, S. S., Germain, C., Fu, H., Larkin, F., & George, A. J. T. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5793 · Cited by 89
The Janus face of dendritic cells in cancer
Chaput, N., Conforti, R., Viaud, S., Spatz, A., & Zitvogel, L. (2008) · Oncogene · doi:10.1038/onc.2008.270 · Cited by 89
Creelan, B., Antonia, S. J., Bepler, G., Garrett, T. J., Simon, G. R., & Soliman, H. H. (2013) · OncoImmunology · doi:10.4161/onci.23428 · Cited by 86
Self-citationAgaugué, S., Perrin‐Cocon, L., Coutant, F., André, P., & Lotteau, V. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2061 · Cited by 87
OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity
Poropatich, K., Dominguez, D., Chan, W., Andrade, J., Zha, Y., Wray, B. D., Miska, J. M., Qin, L., Cole, L. E., Coates, S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131992 · Cited by 85
Ex vivo expansion of CD4+CD25+ T regulatory cells for immunosuppressive therapy
Trzonkowski, P., Szaryńska, M., Myśliwska, J. M., & Myśliwski, A. (2008) · Cytometry Part A · doi:10.1002/cyto.a.20659 · Cited by 85
Local Expression of Indoleamine 2,3-Dioxygenase Protects Engraftment of Xenogeneic Skin Substitute
Li, Y., Tredget, E. E., Ghaffari, A., Lin, X., Kilani, R. T., & Ghahary, A. (2005) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700022 · Cited by 86
López, A., Alegre, E., LeMaoult, J., Carosella, E. D., & GONZALEZ, A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.01.007 · Cited by 88
Gibney, G. T., Hamid, O., Lutzky, J., Olszanski, A. J., Mitchell, T. C., Gajewski, T. F., Chmielowski, B., Hanks, B. A., Zhao, Y., Newton, R. C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0562-8 · Cited by 84
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 85
Challenges and prospects of immunotherapy as cancer treatment
Rescigno, M., Avogadri, F., & Curigliano, G. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.07.003 · Cited by 84
Tryptophan degradation in patients with gynecological cancer correlates with immune activation
Schroecksnadel, K., Winkler, C., Fuith, L. C., & Fuchs, D. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.10.033 · Cited by 85
Plasmacytoid dendritic cells and cancer
Vermi, W., Soncini, M., Melocchi, L., Sozzani, S., & Facchetti, F. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0411190 · Cited by 90
Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Liu, X., Newton, R., Friedman, S., & Scherle, P. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909790192374 · Cited by 83
Makala, L., Baban, B., Lemos, H. D. P., El‐Awady, A., Chandler, P., Hou, D., Munn, D. H., & Mellor, A. L. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq095 · Cited by 82
Self-citationComı́n-Anduix, B., Lee, Y., Jalil, J., Algazi, A. P., de la Rocha, P., Camacho, L. H., Bozon, V. A., Bulanhagui, C. A., Seja, E., Villanueva, A., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-22 · Cited by 82
John, R., & Nelson, P. J. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007030273 · Cited by 80
Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor
Song, X., Si, Q., Qi, R., Liu, W., Li, M., Guo, M.-Y., Wei, L., & Yao, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.800630 · Cited by 79
Murakami, Y., Hoshi, M., Imamura, Y., Arioka, Y., Yamamoto, Y., & Saito, K. (2013) · Mediators of Inflammation · doi:10.1155/2013/391984 · Cited by 86
Kavousanaki, M., Makrigiannakis, A., Boumpas, D. T., & Verginis, P. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25037 · Cited by 78
Still, R., & Brennecke, S. P. (2017) · Obstetric Medicine · doi:10.1177/1753495x17695001 · Cited by 78
Immunomodulatory Bonds of the Partnership between Dendritic Cells and T Cells
Bourque, J., & Hawiger, D. (2018) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2018026790 · Cited by 79
Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level
Pillozzi, S., Bernini, A., Palchetti, I., Crociani, O., Antonuzzo, L., Campanacci, D. A., & Scoccianti, G. (2021) · Cancers · doi:10.3390/cancers13123044 · Cited by 78
Wobser, M., Voigt, H., Houben, R., Eggert, A. O., Freiwald, M., Kaemmerer, U., Kaempgen, E., Schrama, D., & Becker, J. C. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0256-1 · Cited by 77
Yu, J., Sun, J., Wang, S. E., Li, H., Cao, S., Cong, Y., Liu, J., & Ren, X. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/469135 · Cited by 76
Functional Diversity and Plasticity of Human Dendritic Cell Subsets
Ito, T., Liu, Y.-J., & Kadowaki, N. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05012 · Cited by 76
IFN‐γ‐induced IDO and WRS expression in microglia is differentially regulated by IL‐4
Yadav, M. C., Burudi, E. M. E., Alirezaei, M., Flynn, C. C., Watry, D. D., Lanigan, C. M. S., & Fox, H. S. (2007) · Glia · doi:10.1002/glia.20544 · Cited by 76
The cross-talk between dendritic and regulatory T cells: good or evil?
Hubert, P., Jacobs, N., Caberg, J., Boniver, J., & Delvenne, P. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1106694 · Cited by 79
Synovial Autoreactive T Cells in Rheumatoid Arthritis Resist IDO-Mediated Inhibition
Zhu, L., Ji, F., Wang, Y., Zhang, Y., Liu, Q., Zhang, J. Z., Matsushima, K., Cao, Q., & Zhang, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.11.8226 · Cited by 77
Towards a Genetic Definition of Cancer-Associated Inflammation
Prendergast, G. C., Metz, R. A., & Muller, A. J. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091173 · Cited by 74
Microenvironment of Tumor-Draining Lymph Nodes: Opportunities for Liposome-Based Targeted Therapy
Chandrasekaran, S., & King, M. R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151120209 · Cited by 74
Research Progress of Indoleamine 2,3-Dioxygenase Inhibitors
Jiang, T., Sun, Y., Yin, Z., Feng, S., Sun, L., & Li, Z. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.151 · Cited by 73
Onodera, T., Jang, M. H., Guo, Z., Yamasaki, M., Hirata, T., Bai, Z., Tsuji, N. M., Nagakubo, D., Yoshie, O., Sakaguchi, S., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804116 · Cited by 78
Suppressive Influences in the Immune Response to Cancer
Bronte, V., & D, S. M. M. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181837276 · Cited by 73
Fallarino, F., Orabona, C., Vacca, C., Bianchi, R., Gizzi, S., Asselin‐Paturel, C., Fioretti, M. C., Trinchieri, G., Grohmann, U., & Puccetti, P. (2005) · International Immunology · doi:10.1093/intimm/dxh321 · Cited by 76
Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond
Teoh, S. T., & Lunt, S. Y. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1406 · Cited by 77
Next generation immune-checkpoints for cancer therapy
Donini, C., D’Ambrosio, L., Grignani, G., Aglietta, M., & Sangiolo, D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.02.79 · Cited by 74
IL‐10 from plasmacytoid dendritic cells promotes angiogenesis in the early stage of endometriosis
Suen, J., Chang, Y., Shiu, Y., Hsu, C., Sharma, P., Chiu, C., Chen, Y., Hour, T., & Tsai, E. (2019) · The Journal of Pathology · doi:10.1002/path.5339 · Cited by 72
Metabolic Drivers of Invasion in Glioblastoma
Garcia, J. H., Jain, S., & Aghi, M. K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.683276 · Cited by 75
Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases
Yuasa, H. J., Ball, H. J., Ho, Y. F., Austin, C., Whittington, C. M., Belov, K., Maghzal, G. J., Jermiin, L. S., & Hunt, N. H. (2009) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/j.cbpb.2009.02.002 · Cited by 72
Ouabed, A., Hubert, F., Chabannes, D., Gautreau‐Rolland, L., Heslan, M., & Josien, R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.5862 · Cited by 72
Kesarwani, P., Prabhu, A. H., Kant, S., Kumar, P., Graham, S. F., Buelow, K. L., Wilson, G. D., Miller, C. R., & Chinnaiyan, P. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0041 · Cited by 73
Rodrı́guez, P. C., & Ochoa, A. C. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.10.001 · Cited by 76
Mechanisms Involved in Synergistic Anticancer Immunity of Anti-4-1BB and Anti-CD4 Therapy
Choi, B. K., Kim, Y. H., Kang, W. J., Lee, S. K., Kim, K. H., Shin, S. M., Yokoyama, W. M., Kim, T. Y., & Kwon, B. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1056 · Cited by 71
Engineering DNA Nanoparticles as Immunomodulatory Reagents that Activate Regulatory T Cells
Huang, L., Lemos, H. D. P., Li, L., Li, M., Chandler, P., Baban, B., McGaha, T. L., Ravishankar, B., Lee, J. R., Munn, D. H., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103668 · Cited by 71
Self-citationPhysiologic Control of IDO Competence in Splenic Dendritic Cells
Baban, B., Chandler, P., Johnson, B. A., Huang, L., Li, M., Sharpe, M. L., Francisco, L. M., Sharpe, A. H., Blazar, B. R., Munn, D. H., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100276 · Cited by 70
Self-citationTumor Antigen Cross‐Presentation and the Dendritic Cell: Where it All Begins?
McDonnell, A. M., Robinson, B. W. S., & Currie, A. J. (2010) · Journal of Immunology Research · doi:10.1155/2010/539519 · Cited by 75
Inaba, T., Ino, K., Kajiyama, H., Shibata, K., Yamamoto, E., Kondo, S., Umezu, T., Nawa, A., Takikawa, O., & Kikkawa, F. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.02.028 · Cited by 70
IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma
Blair, A. B., Kleponis, J., Thomas, D. L., Muth, S. T., Murphy, A. G., Kim, V., & Zheng, L. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124077 · Cited by 70
Ma, M. W., Medicherla, R. C., Qian, M., de Miera, E. V., Friedman, E. B., Berman, R. S., Shapiro, R. L., Pavlick, A. C., Ott, P. A., Bhardwaj, N., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.43 · Cited by 69
谷崎, 優., Kobayashi, A., Toujima, S., Shiro, M., Mizoguchi, M., Mabuchi, Y., Yagi, S., Minami, S., Takikawa, O., & Ino, K. (2014) · Cancer Science · doi:10.1111/cas.12445 · Cited by 69
Ueno, A., Cho, S., Lu, C. Y., Wang, J., Hou, S., Nakano, H., Santamaría, P., & Yang, Y. (2007) · Diabetes · doi:10.2337/db06-1727 · Cited by 75
Kesarwani, P., Kant, S., Zhao, Y., Prabhu, A. H., Buelow, K. L., Miller, C. R., & Chinnaiyan, P. (2023) · Nature Communications · doi:10.1038/s41467-023-37170-z · Cited by 69
Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma
Urakawa, H., Nishida, Y., Nakashima, H., Shimoyama, Y., Nakamura, S., & Ishiguro, N. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-009-9290-7 · Cited by 69
The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
Sørensen, R. B., Berge-Hansen, L., Junker, N., Hansen, C. A., Hadrup, S. R., Schumacher, T. N., Svane, I. M., Becker, J. C., Straten, P. T., & Andersen, M. H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006910 · Cited by 68
Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma
Hargadon, K. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01594 · Cited by 69
Reprogramming of sentinel lymph node microenvironment during tumor metastasis
Li, Y.-L., & Hung, W. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00868-1 · Cited by 67
Li, J., Giver, C. R., Lu, Y., Hossain, M. S., Akhtari, M., & Waller, E. K. (2009) · Immunotherapy · doi:10.2217/imt.09.32 · Cited by 68
Blaschitz, A., Gauster, M., Fuchs, D., Lang, I., Maschke, P., Ulrich, D., Karpf, E., Takikawa, O., Schimek, M. G., Dohr, G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021774 · Cited by 67
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Metadata
- Authors
- Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L.
- Affiliations
- Augusta University (US)
- University of South Florida (US)
- Corresponding author
- Munn, David H.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2004-07-15
- Volume
- 114
- Issue
- 2
- Pages
- 280-290
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2143565660
- Cited by
- 852
- References
- 85
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 24 · 2023: 15 · 2022: 32 · 2021: 37 · 2020: 34 · 2019: 29 · 2018: 31 · 2017: 40 · 2016: 27 · 2015: 45 · 2014: 38 · 2013: 53 · 2012: 39
- FWCI
- 19.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Carlos and Marguerite Mason Trust
- National Institutes of Health
- National Cancer Institute (R01CA096651, R01 CA103220)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD041187)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- indoleamine 2,3-dioxygenase, plasmacytoid dendritic cells, tumor-draining lymph nodes, immunosuppression, T cell anergy, tumor antigen presentation, CD19, 1-methyl-D-tryptophan, antitumor immunity, regulatory T cells, mixed lymphocyte reaction
- MeSH terms
- Animals, Antigen-Presenting Cells, Dendritic Cells, Female, Humans, Immunosuppression Therapy, Lymph Nodes, Lymphocyte Activation, Mice, Inbred Strains, Neoplasms, Random Allocation, T-Lymphocytes, Tryptophan Oxygenase, Survival Rate, Mice, Knockout, Antigens, CD19, Adoptive Transfer, CD11c Antigen, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
